Prosecution Insights
Last updated: October 25, 2026

Guangzhou Hc New Drug Research Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Guangzhou Hc New Drug Research Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 examiner and 1 art unit, so the available record presents one focused examination assignment.

BAUER, BRIANNA LEE is the busiest examiner, with 1 pending matter. The next prosecution step can be tailored to that examiner’s review.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BAUER, BRIANNA LEE 1 66.7% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18691158 PHARMACEUTICAL COMPOSITION CONTAINING BETA-LACTAM COMPOUND AND USE THEREOF BAUER, BRIANNA LEE —

Top Art Units

Art UnitApps
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18691158 PHARMACEUTICAL COMPOSITION CONTAINING BETA-LACTAM COMPOUND AND USE THEREOF BAUER, BRIANNA LEE 1623 §103§112Other Non-Final OA — Pending Mar 12, 2024

Managing Guangzhou Hc New Drug Research Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Guangzhou Hc New Drug Research Co. Ltd. have?

Guangzhou Hc New Drug Research Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Guangzhou Hc New Drug Research Co. Ltd. applications?

Brianna Lee Bauer has the most, with 1 of Guangzhou Hc New Drug Research Co. Ltd.'s pending office actions.

What technology area are Guangzhou Hc New Drug Research Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month